It would appear pharmaceuticals and biotechnology is still a fertile industry for dealmaking.
Novo Holdings, the largest shareholder in Danish drugs giant Novo Nordisk, just announced the $16.5 billion takeover of US-listed Catalent, provider of delivery technologies, development, drug manufacturing, biologics, gene therapies and consumer health products...
Bloomberg dug out the biggest takeover scoop of the weekend.
The financial media giant revealed that Danaher Corporation, the US-listed life sciences giant, has recently expressed an interest in buying Catalent, a healthcare contract manufacturer.
Bloomberg suggests Danaher indicated it could be willing to pay a significant premium for Catalent, so the latter's shares may be sharply up on Monday...
Betaville notes rivals at StreetInsider have picked up on the Repligen Corporation takeover rumour that has been doing the rounds in the last few days.
According to StreetInsider, Catalent - a US-listed biopharmaceutical company - has been circling Repligen, which makes materials used in the manufacture of biological drugs...